Tags

Type your tag names separated by a space and hit enter

Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients.
Clin Microbiol Infect 2007; 13(3):264-8CM

Abstract

The main aim of this study was to evaluate the clinical outcome and costs of nosocomial and community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S. aureus (MRSA) bloodstream infection (BSI) in patients undergoing haemodialysis. A multicentre retrospective study was conducted that included 109 patients with end-stage renal disease and S. aureus BSI who were hospitalised in three German centres between 1999 and 2005. Nosocomial and community-acquired infections were analysed separately with regard to costs and outcome. Forty-nine (45%) patients had nosocomial infection. Compared to patients with community-acquired infection, these patients were more likely to have had BSI caused by MRSA (40.8% vs. 13.3%, p <0.05). BSI was the initial reason for admission for 33 (55%) patients who had community-acquired infection. The mean length of hospitalisation was 24 days for patients with community-acquired infection and 51 days for patients with nosocomial infection (p <0.05). Costs per treatment episode were 20,024 Euros for nosocomial infection vs. 9554 Euros for community-acquired infection (p <0.05). The average treatment costs for patients with MSSA BSI were <50% of those for patients with MRSA BSI (10,573 vs. 24,931 Euros, p <0.05). S. aureus BSI is an underlying cause of substantial health risk and high morbidity among the haemodialysis-dependent population, who are already at high-risk for other reasons. This study also highlighted differences according to the source of BSI, including costs arising from hospitalisation and treatment.

Authors+Show Affiliations

Faculty of Public Health, Health Economics and Health Management, University of Bielefeld, Bielefeld, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

17391380

Citation

Greiner, W, et al. "Clinical Outcome and Costs of Nosocomial and Community-acquired Staphylococcus Aureus Bloodstream Infection in Haemodialysis Patients." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 13, no. 3, 2007, pp. 264-8.
Greiner W, Rasch A, Köhler D, et al. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect. 2007;13(3):264-8.
Greiner, W., Rasch, A., Köhler, D., Salzberger, B., Fätkenheuer, G., & Leidig, M. (2007). Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 13(3), pp. 264-8.
Greiner W, et al. Clinical Outcome and Costs of Nosocomial and Community-acquired Staphylococcus Aureus Bloodstream Infection in Haemodialysis Patients. Clin Microbiol Infect. 2007;13(3):264-8. PubMed PMID: 17391380.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. AU - Greiner,W, AU - Rasch,A, AU - Köhler,D, AU - Salzberger,B, AU - Fätkenheuer,G, AU - Leidig,M, PY - 2007/3/30/pubmed PY - 2007/4/25/medline PY - 2007/3/30/entrez SP - 264 EP - 8 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin. Microbiol. Infect. VL - 13 IS - 3 N2 - The main aim of this study was to evaluate the clinical outcome and costs of nosocomial and community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S. aureus (MRSA) bloodstream infection (BSI) in patients undergoing haemodialysis. A multicentre retrospective study was conducted that included 109 patients with end-stage renal disease and S. aureus BSI who were hospitalised in three German centres between 1999 and 2005. Nosocomial and community-acquired infections were analysed separately with regard to costs and outcome. Forty-nine (45%) patients had nosocomial infection. Compared to patients with community-acquired infection, these patients were more likely to have had BSI caused by MRSA (40.8% vs. 13.3%, p <0.05). BSI was the initial reason for admission for 33 (55%) patients who had community-acquired infection. The mean length of hospitalisation was 24 days for patients with community-acquired infection and 51 days for patients with nosocomial infection (p <0.05). Costs per treatment episode were 20,024 Euros for nosocomial infection vs. 9554 Euros for community-acquired infection (p <0.05). The average treatment costs for patients with MSSA BSI were <50% of those for patients with MRSA BSI (10,573 vs. 24,931 Euros, p <0.05). S. aureus BSI is an underlying cause of substantial health risk and high morbidity among the haemodialysis-dependent population, who are already at high-risk for other reasons. This study also highlighted differences according to the source of BSI, including costs arising from hospitalisation and treatment. SN - 1198-743X UR - https://www.unboundmedicine.com/medline/citation/17391380/Clinical_outcome_and_costs_of_nosocomial_and_community_acquired_Staphylococcus_aureus_bloodstream_infection_in_haemodialysis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(14)62744-0 DB - PRIME DP - Unbound Medicine ER -